Immunovant (IMVT) Equity Average (2019 - 2026)
Immunovant filings provide 7 years of Equity Average readings, the most recent being $752.9 million for Q4 2025.
- Quarterly Equity Average rose 87.84% to $752.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $752.9 million through Dec 2025, up 87.84% year-over-year, with the annual reading at $662.6 million for FY2025, 35.19% up from the prior year.
- Equity Average hit $752.9 million in Q4 2025 for Immunovant, up from $564.1 million in the prior quarter.
- Across five years, Equity Average topped out at $752.9 million in Q4 2025 and bottomed at $275.8 million in Q3 2023.
- Average Equity Average over 5 years is $480.4 million, with a median of $459.4 million recorded in 2022.
- The largest annual shift saw Equity Average surged 291.21% in 2021 before it crashed 33.71% in 2023.
- Immunovant's Equity Average stood at $520.8 million in 2021, then decreased by 22.19% to $405.2 million in 2022, then increased by 14.9% to $465.6 million in 2023, then decreased by 13.91% to $400.8 million in 2024, then soared by 87.84% to $752.9 million in 2025.
- Per Business Quant, the three most recent readings for IMVT's Equity Average are $752.9 million (Q4 2025), $564.1 million (Q3 2025), and $658.0 million (Q2 2025).